Bishop graces Genesis board
This article was originally published in Scrip
Hans Bishop has joined the board of Genesis Biopharma, a biotech developing targeted cancer immunotherapies, bringing the total number of board members to eight. Most recently, Mr Bishop served as chief operating officer for Dendreon. Prior to that, he was president of the specialty medicine business unit at Bayer Healthcare.